These observations suggest that icotinib-induced upregulation of Cbl-b is responsible, at least in part, for the antitumor effect of icotinib via the inhibition of PI3K/Akt and MAPK pathways in EGFR-mutated NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.